Cortexin vs N-Acetyl Selank

Polypeptide bioregulator from bovine cortex; modulates neurotransmitter activity; activates GABA and dopamine systems; reduces excitotoxicity; stimulates neuronal repair

Cortexin is a polypeptide bioregulator derived from porcine cerebral cortex, used clinically in Russia and Eastern Europe as a neuroprotective and nootropic agent for stroke, traumatic brain injury, and chronic cerebrovascular disorders. It contains a complex mixture of tissue-specific neuropeptides, amino acids, and microelements proposed to support neuronal survival, reduce excitotoxic damage, and promote neurotrophic factor expression in injured brain tissue. Russian clinical trials have examined cortexin in acute ischemic stroke rehabilitation and other neurological conditions, with results suggesting potential benefit in functional recovery, though studies are predominantly published in Russian-language journals with limited methodological transparency by international standards. Cortexin is not FDA-approved; it is a licensed prescription drug in Russia and several post-Soviet states, where it has regulatory approval for neurological indications. Cortexin administration: in clinical settings where it is approved, cortexin is administered by intramuscular injection, typically as a 10 mg dose reconstituted in saline or procaine. Clinical courses in Russian practice involve daily injections over 10-day cycles, repeated 1–2 times per year for chronic neurological conditions. This administration pattern is common to several Russian polypeptide bioregulators, including cerebrolysin — another porcine-derived peptide mixture with a broader international clinical trial dataset — and cortagen, a cardiac-focus bioregulator from the same pharmacological class. Cortexin is the cerebral-cortex-specific member of this class; cortagen targets cardiovascular tissue, and thymalin targets thymic/immune tissue. Provider availability for cortexin outside Russia is limited compared to peptides with international regulatory approvals; it is occasionally carried by compounding pharmacies and specialized nootropic suppliers. The PeptideBase cognitive peptides directory lists verified providers who carry neuroprotective peptide compounds.

Tuftsin-derived heptapeptide with structural modifications that resist enzymatic degradation. Modulates GABA-A receptor complex, increases enkephalin levels in limbic system, and influences serotonin metabolism.

N-Acetyl-Selank is an acetylated derivative of selank (TKPRPGP), a synthetic heptapeptide anxiolytic developed from a tuftsin-based sequence; N-acetylation at the N-terminus is proposed to improve resistance to enzymatic degradation and potentially alter blood-brain barrier permeability relative to the parent compound, with the expectation of enhanced CNS bioavailability and duration of action. The pharmacological rationale derives from the parent compound selank, which acts through GABAergic, serotonergic, and enkephalinergic pathways to produce anxiolytic and nootropic effects in preclinical models and limited Russian human clinical studies; N-acetyl-selank is presumed to retain similar receptor interactions with modified pharmacokinetics. No publications indexed in PubMed specifically examine N-acetyl-selank as a distinct compound; no human clinical trials, independent preclinical studies, or pharmacokinetic comparisons with the parent selank exist in the indexed scientific literature, representing a complete absence of specific evidence for this analog beyond its structural modification. N-Acetyl-Selank has no FDA approval and no approved indication in any jurisdiction; it is available through research chemical suppliers as a purported improvement on selank, but its pharmacological properties, safety profile, and clinical utility in humans are entirely uncharacterized as a distinct compound.